Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a601146
  • US: X (Contraindicated)
Routes of
Subcutaneous implant
ATC code L02AE05 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 92%
Protein binding 70%
Metabolism Hepatic
Biological half-life 4.0 hours
Excretion Undetermined
CAS Number 76712-82-8 N
PubChem (CID) 25077993
ChemSpider 10482012 YesY
UNII H50H3S3W74 YesY
KEGG D02369 YesY
ECHA InfoCard 100.163.860
Chemical and physical data
Formula C66H86N18O12
Molar mass 1323.5 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency.[1] When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

Histrelin is marketed by Endo Pharmaceuticals under the brand names Vantas and Supprelin LA.

Medical uses

Histrelin is used to treat hormone-sensitive cancers of the prostate in men and uterine fibroids in women. In addition, histrelin has been proven to be highly effective in treating central precocious puberty in children.[2][3]

It is available as a daily intramuscular injection.

Histrelin is also available in a 12-month subcutaneous implant (Vantas) for the palliative treatment of advanced prostate cancer, since 2005 in the US, and since Jan 2010 in the UK.[4]

A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved on May 3, 2007 by the U.S. Food and Drug Administration.

Histrelin is also part of the primary care protocol in transgender children/youth, and is used in suppressing cis-sex puberty, until the patient is ready to begin cross-sex hormonal therapy.[5]

Adverse effects

Side effects are mainly due to low testosterone levels and include headache, hot flashes, reduced libido, and erectile dysfunction.[6]


In a process known as downregulation, daily stimulation of pituitary gonadotropes causes them to become desensitized to the effects of histrelin. As a consequence, levels of LH and FSH fall after a short period of time. From that point forward, as long as histrelin is administered, the levels of LH and FSH in the blood remain low.[7][8]

This prolonged lowering of LH and FSH levels is the rationale for therapy using GnRH agonists. Since LH and FSH stimulate the gonads to produce estrogens and androgens in females and males respectively, histrelin can effectively be used to decrease the sex steroids in the blood of patients.


  1. Histrelin acetate (Vantas) - New Drug Bulletins
  2. Histrelin consumer information
  3. Eugster, Erica A.; William Clarke; et al. (2007). "Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial". J Clin Endocrinol Metab. 92 (5): 16971704. doi:10.1210/jc.2006-2479. PMID 17327379. Retrieved 2007-10-17.
  4. "Implant inserted under the skin ends the misery of prostate jabs". Daily Mail. 6 April 2010. p. 48. Archived from the original on 2012-06-23.
  5. "Primary Care Protocol for Transgender Patient Care: Hormone Administration". transhealth.ucsf.edu. Archived from the original on 2012-01-17. Retrieved 2015-09-29.
  6. Drugs.com: Histrelin Monograph
  7. Mutschler, Ernst; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. pp. 372–3. ISBN 3-8047-1763-2.
  8. Wuttke, W; Jarry, H; Feleder, C; Moguilevsky, J; Leonhardt, S; Seong, J. Y.; Kim, K (1996). "The neurochemistry of the GnRH pulse generator". Acta neurobiologiae experimentalis. 56 (3): 707–13. PMID 8917899.

This article is issued from Wikipedia - version of the 9/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.